As a novel antidiabetic agent, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are seeing an increasing application in the management of patients with T2DM, given their remarkable efficacy in regulating blood sugar levels without posing an elevated risk of hypoglycemic episodes or weight gain (Drucker and Nauck, 2006; Nauck, 2016). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.